Kirsters Baish| According to a recent report, Israeli scientists have found a cure for cancer, and as the Daily Caller explains, the scientists have found a cure not just for “certain forms of cancer, but a complete cure for the deadly disease.”
The Daily Caller reports:
According to Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd. (AEBi) and CEO Dr. Ilan Morad, their treatment will not need time for the body to acculturate to it before it works. Aridor stated, “We believe we will offer in a year’s time a complete cure for cancer. … Our cancer cure will be effective from day one … and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.”
The Jerusalem Post reported, “An estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).”
The cancer treatment is called MuTaTo, which is short for multi-target toxin. It works similarly to antibiotics in the sense that it targets bacteria.
The Daily Caller explains that “MuTaTo is based on SoAP technology, which works by finding, binding and removing bacteria by utilizing bacteriophage-derived proteins. Bacteriophages are viruses that infect bacteria.”
The Daily Caller explains:
MuTaTo inserts DNA coding for a protein into a bacteriophage. Once inside, the protein shows up on the phage’s surface, making it apparent to researchers who can use the phages to find interactions with other proteins, DNA sequences and small molecules. Unlike 2018 Nobel Prize-winning scientists George Smith and Gregory Winter, who used phage display to evolve new proteins or antibodies, the Israelis are producing peptides, which Morad says are better equipped for the job because they are smaller, less expensive and less difficult to manage.
Morad explained that in the company’s first attempts worked on finding “individual novel peptides for specific cancers.” However, he and his colleague, Dr. Hanan Itzhaki, decided to take it further. Morad made it clear that most anti-cancer drugs go after a specific target that is either on or in a cancer cell. He explained that “they often trigger a mutation that makes the drug ineffective.”
The Jerusalem Post explains, however, that MuTato uses “a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically.”
Morad stated that the technique “made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer … The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used. Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
He explained that MuTato is the answer since it goes after numerous targets, destroying the proteins on the cancer cell. Morad has also explained that because the peptide areas of MuTaTo are so tiny and flexible, they are able to “penetrate areas other drugs fail to reach.”
Morad said, “This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug.”
He said that the treatment could potentially reduce side effects, which the Daily Caller explain “often arise because cancer treatments either connect with the wrong or additional targets, or the right targets on healthy cells.”
Aridor finished off by saying, “Our results are consistent and repeatable.”